Chiesi’s Rare Disease Strategy Expands to Genetic Meds via Alliance With CRISPR Startup Arbor
In the five years since Italy-based Chiesi Group established its rare disease division in Boston, the unit has landed regulatory ...
In the five years since Italy-based Chiesi Group established its rare disease division in Boston, the unit has landed regulatory ...
Drugs for the rare hormone disorder acromegaly include older engineered peptides administered as frequent injections. A new FDA approval brings ...
A deep dive into public Facebook posts uncovers the real-world side effect patterns of GLP-1 medications, revealing what users actually ...
Regeneron Pharmaceuticals is expanding its cancer drug lineup with FDA approval of a bispecific antibody it developed for multiple myeloma, ...
ADHD stimulant meds don't increase children's risk of psychosis, a new study says. Analysis of stimulant prescriptions among nearly 8,400 ...
A pharmaceutical company that allegedly paid doctors kickbacks to push their HIV/AIDS drugs has agreed to pay a fine of ...
A PepGen drug in development for myotonic dystrophy type 1 (DM1) has encouraging early human data that suggest it could ...
For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...
Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly ...
GLP-1 drugs currently available for weight loss are administered as once-weekly injections. Verdiva Bio also aims to bring to patients ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.